サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411510

気管支拡張症治療薬市場：薬剤クラス別、投与経路別、エンドユーザー別-2024～2030年の世界予測

Bronchiectasis Drugs Market by Drug Class (Anti-inflammatory Agents, Antibiotics, Bronchodilators), Route of Administration (Inhalation, Intravenous, Oral), End-Users - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 181 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
気管支拡張症治療薬市場：薬剤クラス別、投与経路別、エンドユーザー別-2024～2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

気管支拡張症治療薬市場規模は2023年に13億9,000万米ドルと推計され、2024年には15億米ドルに達し、CAGR 9.86%で2030年には27億米ドルに達すると予測されます。

気管支拡張症治療薬の世界市場

主な市場の統計
基準年[2023］ 13億9,000万米ドル
予測年[2024］ 15億米ドル
予測年 [2030] 27億米ドル
CAGR（%） 9.86%
気管支拡張症治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは気管支拡張症治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、気管支拡張症治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-気管支拡張症治療薬市場の市場規模および予測は？

2-気管支拡張症治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-気管支拡張症治療薬市場における技術動向と規制の枠組みは？

4-気管支拡張症治療薬市場における主要ベンダーの市場シェアは？

5-気管支拡張症治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 気道感染症と疾患の増加
      • 呼吸器の健康に対する意識を高める政府の取り組み
      • 短時間作用型と長時間作用型の気管支拡張症治療薬の入力
    • 抑制要因
      • 一般的な気管支拡張症治療薬に対する病原種の耐性
    • 機会
      • 吸入抗生物質や先進的な気管支拡張薬の開発につながるイノベーション
      • 気管支拡張症治療薬を開発するための研究開発活動と臨床試験
    • 課題
      • 気管支拡張症治療薬の安全性と有効性に関する規制上の懸念
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 気管支拡張症治療薬市場薬剤クラス別

  • 抗炎症剤
  • 抗生物質
  • 気管支拡張薬
  • 粘液溶解薬

第7章 気管支拡張症治療薬市場：投与経路別

  • 吸入
  • 静脈内
  • オーラル

第8章 気管支拡張症治療薬市場：エンドユーザー別

  • 診療所
  • 病院
  • 調査

第9章 南北アメリカの気管支拡張症治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の気管支拡張症治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの気管支拡張症治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AdvaCare Pharma
    • AstraZeneca PLC
    • Boehringer Ingelheim International GmbH
    • Cipla Limited
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Limited
    • Lupin Limited
    • Mylan Inc. by Viatris Inc.
    • Nephron Pharmaceuticals Corporation
    • Novartis AG
    • Perrigo Company PLC
    • Pfizer Inc.
    • Prasco Laboratories
    • Ralington Pharma LLP
    • Steris Healthcare Pvt. Ltd.
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd.
    • Zydus Group
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. BRONCHIECTASIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHIECTASIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BRONCHIECTASIS DRUGS MARKET DYNAMICS
  • FIGURE 7. BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 12. BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. BRONCHIECTASIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 15. BRONCHIECTASIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. BRONCHIECTASIS DRUGS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 146. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. BRONCHIECTASIS DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-B1685377A3FA

[181 Pages Report] The Bronchiectasis Drugs Market size was estimated at USD 1.39 billion in 2023 and expected to reach USD 1.50 billion in 2024, at a CAGR 9.86% to reach USD 2.70 billion by 2030.

Global Bronchiectasis Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.39 billion
Estimated Year [2024] USD 1.50 billion
Forecast Year [2030] USD 2.70 billion
CAGR (%) 9.86%
Bronchiectasis Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bronchiectasis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bronchiectasis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bronchiectasis Drugs Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Bronchiectasis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Anti-inflammatory Agents
    • Antibiotics
    • Bronchodilators
    • Mucolytics
  • Route of Administration
    • Inhalation
    • Intravenous
    • Oral
  • End-Users
    • Clinic
    • Hospital
    • Research Institute
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bronchiectasis Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bronchiectasis Drugs Market?

3. What are the technology trends and regulatory frameworks in the Bronchiectasis Drugs Market?

4. What is the market share of the leading vendors in the Bronchiectasis Drugs Market?

5. Which modes and strategic moves are suitable for entering the Bronchiectasis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Bronchiectasis Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of respiratory tract infections and diseases
      • 5.1.1.2. Government initiatives to raise awareness about respiratory health
      • 5.1.1.3. Entry of short-acting and long-acting bronchiectasis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Resistance of pathogenic species to common bronchiectasis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations leading to the development of inhaled antibiotics and advanced bronchodilators
      • 5.1.3.2. R&D activities and clinical trials to develop bronchiectasis drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory concerns about the safety and efficacy of bronchiectasis drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Bronchiectasis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-inflammatory Agents
  • 6.3. Antibiotics
  • 6.4. Bronchodilators
  • 6.5. Mucolytics

7. Bronchiectasis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Intravenous
  • 7.4. Oral

8. Bronchiectasis Drugs Market, by End-Users

  • 8.1. Introduction
  • 8.2. Clinic
  • 8.3. Hospital
  • 8.4. Research Institute

9. Americas Bronchiectasis Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bronchiectasis Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bronchiectasis Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AdvaCare Pharma
    • 13.1.2. AstraZeneca PLC
    • 13.1.3. Boehringer Ingelheim International GmbH
    • 13.1.4. Cipla Limited
    • 13.1.5. GlaxoSmithKline PLC
    • 13.1.6. Glenmark Pharmaceuticals Limited
    • 13.1.7. Lupin Limited
    • 13.1.8. Mylan Inc. by Viatris Inc.
    • 13.1.9. Nephron Pharmaceuticals Corporation
    • 13.1.10. Novartis AG
    • 13.1.11. Perrigo Company PLC
    • 13.1.12. Pfizer Inc.
    • 13.1.13. Prasco Laboratories
    • 13.1.14. Ralington Pharma LLP
    • 13.1.15. Steris Healthcare Pvt. Ltd.
    • 13.1.16. Sun Pharmaceutical Industries Limited
    • 13.1.17. Teva Pharmaceutical Industries Ltd.
    • 13.1.18. Zydus Group
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing